Omnicell (NASDAQ:OMCL) Shares Down 7%

Omnicell, Inc. (NASDAQ:OMCL) shares fell 7% during mid-day trading on Wednesday . The stock traded as low as $26.56 and last traded at $26.63. 38,788 shares traded hands during trading, a decline of 93% from the average session volume of 556,987 shares. The stock had previously closed at $28.64.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OMCL. Wells Fargo & Company reduced their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. Benchmark reduced their price objective on Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Finally, Barclays began coverage on Omnicell in a research note on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $42.20.

Omnicell Trading Down 0.4 %

The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $28.15 and a two-hundred day simple moving average of $33.67.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The business had revenue of $258.85 million during the quarter, compared to analysts’ expectations of $256.00 million. Sell-side analysts anticipate that Omnicell, Inc. will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently modified their holdings of OMCL. MetLife Investment Management LLC boosted its position in Omnicell by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock worth $3,000,000 after acquiring an additional 8,257 shares during the period. Rhumbline Advisers boosted its position in Omnicell by 6.4% during the 1st quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock worth $14,386,000 after acquiring an additional 6,657 shares during the period. Great West Life Assurance Co. Can boosted its position in Omnicell by 0.4% during the 1st quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after acquiring an additional 144 shares during the period. Raymond James Trust N.A. boosted its position in Omnicell by 10.9% during the 1st quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock worth $503,000 after acquiring an additional 382 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Omnicell by 0.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock worth $109,901,000 after acquiring an additional 4,839 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.